Literature DB >> 24266919

When to consider liver transplant during the management of chronic liver disease.

Rena K Fox1.   

Abstract

The decision to perform liver transplantation for a particular patient is never the decision of one single individual, although a single individual could preclude transplant as an option if the opportunity for referral is missed. Every physician treating patients with cirrhosis, including primary care physicians and primary gastroenterologists, should watch for the essential turning points at which a patient may become eligible for a transplant referral. Timing of referral could be assessed according to either the type of liver disease or non–disease-specific measures of disease severity. Although the MELD score is an easily accessible and convenient tool it is not as well known as CTP classification, and many cirrhotic patients under long-term management may not be being allocated a MELD score regularly calculated by their primary physicians. Because a slow progression in MELD score may occur without a change in symptoms, reaching the MELD score acceptable for transplant referral may go unrecognized. As generalists face the rising prevalence of NAFLD and the rising prevalence of cirrhosis and HCC from HCV, there will be an increasing need for education in the management of liver disease. It will be necessary for specialists and health care systems to better inform primary care physicians about the recommendations on criteria for transplant referral and the critical windows of opportunity within which they can act. Although there is a recognized knowledge gap that needs to be addressed, once a patient is in medical care, inadequate physician knowledge should never be the cause for late timing or missing the opportunity for referral.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic liver disease; Cirrhosis; Clinical practice; Evaluation; Liver transplantation; Primary care; Referral; Timing

Mesh:

Year:  2013        PMID: 24266919     DOI: 10.1016/j.mcna.2013.09.007

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  5 in total

Review 1.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

2.  Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.

Authors:  Mitchell L Shiffman; Amy M James; April G Long; Philip C Alexander
Journal:  Am J Gastroenterol       Date:  2015-07-28       Impact factor: 10.864

3.  Value and limitations of the BAR-score for donor allocation in liver transplantation.

Authors:  Harald Schrem; Anna-Luise Platsakis; Alexander Kaltenborn; Armin Koch; Courtney Metz; Marc Barthold; Christian Krauth; Volker Amelung; Felix Braun; Thomas Becker; Jürgen Klempnauer; Benedikt Reichert
Journal:  Langenbecks Arch Surg       Date:  2014-09-14       Impact factor: 3.445

4.  Dysregulated Bile Transporters and Impaired Tight Junctions During Chronic Liver Injury in Mice.

Authors:  Tirthadipa Pradhan-Sundd; Ravi Vats; Jacquelyn O Russell; Sucha Singh; Adeola Adebayo Michael; Laura Molina; Shelly Kakar; Pamela Cornuet; Minakshi Poddar; Simon C Watkins; Kari N Nejak-Bowen; Satdarshan P Monga; Prithu Sundd
Journal:  Gastroenterology       Date:  2018-06-30       Impact factor: 22.682

5.  Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma.

Authors:  Juan R Sanabria; Rajan S Kombu; Guo-Fang Zhang; Yana Sandlers; Jizhou Ai; Rafael A Ibarra; Rime Abbas; Kush Goyal; Henri Brunengraber
Journal:  HPB (Oxford)       Date:  2016-10-27       Impact factor: 3.647

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.